Prognostic Factors and Recurrence in Breast Cancer: Experience at the National Cancer Institute of Mexico

Table 1

Baseline demographic and clinical characteristics.

	Recurrence group	control group
Age group
>35	51 (85%)	51 (85%)
≤35	9 (15%)	9 (15%)
Clinical stage
I	1 (1.67%)	1 (1.67%)
IIA	7 (11.67%)	9 (15.00%)
IIB	19 (31.67%)	22 (36.67%)
IIIA	15 (25.00%)	13 (21.67%)
IIIB	14 (23.33%)	15 (25.00%)
IIIC	2 (3.33%)	0
IV	1 (1.67%)	0
Unknown	1 (1.67%)	0
Skin involvement
Yes	14 (23.33%)	14 (23.33%)
No	46 (76.67%)	46 (76.67%)
Clinical lymph node status
N0	13 (21.67%)	13 (21.67%)
N1	33 (55.00%)	33 (55.00%)
N2	14 (23.33%)	14 (23.33%)
Clinical tumor size (cm)
1	1 (1.67%)	3 (5.00%)
2	9 (15.00%)	4 (6.67%)
3	12 (20.00%)	16 (26.67%)
4	6 (10.00%)	11 (18.33%)
5	7 (11.67%)	9 (15.00%)
6	9 (15.00%)	9 (15.00%)
7	5 (8.33%)	3 (5.00%)
8	2 (3.33%)	2 (3.33%)
9	1 (1.67%)	1 (1.67%)
10	2 (3.33%)	1 (1.67%)
11	5 (8.33%)	0
Unknown	1 (1.67%)	1 (1.67%)
Histological type
Ductal	51 (85%)	54 (90.00%)
Lobular	2 (3.33%)	3 (5.00%)
Ductal-lobular	6 (10.00%)	2 (3.33%)
Other	1 (1.67%)	1 (1.67%)
Histological grade
Grade I	1 (1.67%)	2 (3.33%)
Grade II	21 (35.00%)	19 (31.67%)
Grade III	29 (48.33%)	27 (45.00%)
Unknown	9 (15.00%)	12 (20%)
Lymphovascular involvement
Yes	26 (43.33%)	13 (21.67%)
No	34 (34%)	47 (78.33%)
Estrogen receptor status
<20	29 (48.33%)	27 (45.00%)
20–49	8 (13.33%)	11 (18.33%)
50–100	10 (16.67%)	6 (10.00%)
>100	6 (10.00%)	8 (13.33%)
Unknown	7 (11.67%)	8 (13.33%)
Progesterone receptor status
<5	26 (43.33%)	27 (45.00%)
5–30	5 (8.33%)	10 (16.67%)
31–50	2 (3.33%)	1 (1.67%)
51–100	12 (20%)	4 (6.67%)
>100	7 (11.67%)	9 (15.00%)
Unknown	8 (13.33%)	9 (15.00%)
Positive ER PR status	29 (54.7%)	31 (59.6%)
Negative ER PR status	24 (45.2%)	21 (40.3%)
Unknown	7	8
HER2/NEU expression
Negative	32 (76.19%)	27 (81.81%)
Positive	10 (23.81%)	6 (19.19%)
Unknown	18	27
Extracapsular involvement
No	52 (86.67%)	53 (88.33%)
Yes	8 (13.33%)	7 (11.67%)